GridAI Technologies (GRDX) Notes Payables (2015 - 2025)

GridAI Technologies' (GRDX) quarterly Notes Payables came in at $2.0 million in Q4 2025, up 1041.67% on a QoQ basis from $177563.0 in Q2 2024.

GridAI Technologies (GRDX) Notes Payables (2015 - 2025) Analysis & Trends

GridAI Technologies (GRDX) has 11 years of Notes Payables data on file, last reported at $2.0 million in Q4 2025.

Quarterly Notes Payables changed N/A year-over-year to $2.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.0 million (changed N/A YoY) and the FY2025 annual result came in at $2.0 million, changed N/A from the prior year.
Notes Payables grew to $2.0 million in Q4 2025, from $177563.0 in the prior quarter.
In the past five years, Notes Payables ranged from a high of $2.0 million in Q4 2025 to a low of $139569.0 in Q2 2021.
A 5-year average of $502852.0 and a median of $383579.5 in 2023 frame the typical range for Notes Payables.
Annual changes were most pronounced in 2021 — Notes Payables gained 23.96% — and 2022, when it declined 5.89%.
Tracing GRDX's Notes Payables over 5 years: stood at $641236.0 in 2021, then fell by 5.89% to $603494.0 in 2022, then rose by 1.54% to $612784.0 in 2023, then tumbled by 71.02% to $177563.0 in 2024, then soared by 1041.67% to $2.0 million in 2025.
The last three Notes Payables figures came in at $2.0 million (Q4 2025), $177563.0 (Q2 2024), and $386769.0 (Q1 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.90 Bn	131.05 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.10 Bn	78.11 Bn	3.93 Bn
3	Argenx Se	65.56 Bn	60.37 Bn	1.37 Bn
4	Moderna	55.82 Bn	50.68 Bn	52.00 Mn
5	BeOne Medicines	42.14 Bn	37.04 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.67 Bn	28.36 Bn	992.69 Mn
7	BioNTech SE	27.74 Bn	9.35 Bn	668.28 Mn
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn
9	Royalty Pharma	27.38 Bn	26.54 Bn	-
10	GridAI Technologies	5.67 Mn	5.67 Mn	-

Download Data